It appears from all of the posting that those (and their employers) who doubled down on their shorts after the halt did so on the bet the trial design was flawed and there was no way DCVax-L would ever be approved. I doubt many figured a heavy push with the MHRA in conjunction with filing with the FDA. The times are changing from the use of external controls to current (oncology) SOC protocols are no longer cost effective for their outcomes.
I'm staying on the long side. Not much upside left for shorts here. SMH. Peace.
News 
Market Data 
Discover 
AI
